Xenon Pharmaceuticals (XENE) Stock Forecast, Price & News

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xenon Pharmaceuticals in the last year. There are currently 12 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" XENE shares.
View XENE analyst ratings or view top-rated stocks.

13 brokerages have issued 1-year target prices for Xenon Pharmaceuticals' stock. Their XENE share price forecasts range from $45.00 to $60.00. On average, they predict the company's share price to reach $51.50 in the next year. This suggests a possible upside of 32.2% from the stock's current price.
View analysts price targets for XENE or view top-rated stocks among Wall Street analysts.

Xenon Pharmaceuticals' stock was trading at $39.43 at the beginning of 2023. Since then, XENE shares have decreased by 1.2% and is now trading at $38.96.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our XENE earnings forecast.

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) issued its quarterly earnings results on Tuesday, May, 9th. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.62) by $0.01. Xenon Pharmaceuticals had a negative trailing twelve-month return on equity of 20.01% and a negative net margin of 862.06%. During the same period in the previous year, the business earned ($0.35) EPS.

ETFs with the largest weight of Xenon Pharmaceuticals (NASDAQ:XENE) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), ALPS Medical Breakthroughs ETF (SBIO), First Trust Multi-Manager Small Cap Opportunities ETF (MMSC), Virtus LifeSci Biotech Clinical Trials ETF (BBC), iShares Biotechnology ETF (IBB), Nuveen ESG Small-Cap ETF (NUSC), Invesco Nasdaq Biotechnology ETF (IBBQ) and ProShares Ultra Nasdaq Biotechnology (BIB).

Based on aggregate information from My MarketBeat watchlists, some companies that other Xenon Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Corbus Pharmaceuticals (CRBP), Nektar Therapeutics (NKTR), TG Therapeutics (TGTX), Viking Therapeutics (vktx), Sangamo Therapeutics (SGMO), Arbutus Biopharma (ABUS), OPKO Health (OPK) and Spectrum Pharmaceuticals (SPPI).

Xenon Pharmaceuticals trades on the NASDAQ under the ticker symbol "XENE."

Xenon Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include FMR LLC (7.49%), Braidwell LP (3.36%), Pictet Asset Management SA (3.18%), Commodore Capital LP (2.90%), Perceptive Advisors LLC (2.88%) and BVF Inc. IL (2.88%). Insiders that own company stock include Christopher John Kenney, Frank A Holler, Gary Patou, Ian Mortimer, James R Empfield, Seggern Christopher Von, Sherrington Robin and Simon N Pimstone.
View institutional ownership trends.

Shares of XENE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of XENE stock can currently be purchased for approximately $38.96.

Xenon Pharmaceuticals (NASDAQ:XENE) has a market capitalization of $2.48 billion and generates $9.43 million in revenue each year. The biopharmaceutical company earns $-125,370,000.00 in net income (profit) each year or ($2.32) on an earnings per share basis.

The company employs 149 workers across the globe.

Xenon Pharmaceuticals' mailing address is 200 - 3650 GILMORE WAY, BURNABY A1, V5G 48W. The official website for the company is www.xenon-pharma.com. The biopharmaceutical company can be reached via phone at (604) 484-3300, via email at investors@xenon-pharma.com, or via fax at 604-484-3450.